drugset / Trial / NCT00685022

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

NCT00685022

Phase 2 Completed 49 enrolled Sumitomo Pharma America, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to compare the safety and tolerability of levalbuterol HFA metered dose inhaler (MDI) versus racemic albuterol HFA MDI.

Timeline

Start
2003-06
Primary completion
2003-08
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Levalbuterol Other / unclassified 45 ug
Comparator racemic albuterol Unknown 90 ug

Indications